Z-VAD-FMK

For research use only. Not for use in humans.

Catalog No.S7023

501 publications

Z-VAD-FMK Chemical Structure

Molecular Weight(MW): 467.49

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Size Price Stock Quantity  
USD 117 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Z-VAD-FMK has been cited by 501 publications

Purity & Quality Control

Choose Selective Caspase Inhibitors

Biological Activity

Description Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.
Features A key compound for apoptosis studies.
Targets
Pan-caspase [1]
(THP.1, Jurkat T-cells)
In vitro

Z-VAD-FMK (10 mM) inhibits apoptosis in THP.1 cells. Z-VAD-FMK (10 μM) inhibits activation of PARP protease activity in control THP.1 cell lysates. Z-VAD-FMK (10 mM) inhibits the processing of CPP32 in intact THP.1 and Jurkat cells. [1] Z-VAD-FMK (50 μM) cotreatment abolishes the apoptotic morphology of camptothecin-treated HL60 cells. Z-VAD-FMK (50 μM) blocks camptothecin-induced DNA fragmentation in HL60 cells. [2] Z-VAD-FMK (50 μM) inhibits cell death following dSMN dsRNA-induced apoptosis in S2 cells. Z-VAD-FMK (50 μM) increases the percentage of transfected cells surviving from 26% to 63% in S2 cells. [3] Z-VAD-FMK (> 100 μM) enhances TNFα-induced neutrophil apoptosis, lower concentrations (1-30 μM) completely blocks TNFα-stimulated apoptosis in human neutrophils. [4] Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes. Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes detected with the TUNEL assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
GC1a MUnBdI9xfG:|aYOgRZN{[Xl? M2fvNFUx|ryP MW[yOIg> NV3iXpoycW6maXPheIV{KGFicILveIVkfGm4ZTDl[oZm[3RiYXfhbY5{fCCndH;wc5Nq\GV? M1TTOFI3OTZ7MEe1
HGL5 M1Xad2Fxd3C2b4Ppd{BCe3OjeR?= NGmxdHM2OM7:TR?= NUPWO4ExOjSq NWTQOJp[cW6maXPheIV{KGFicILveIVkfGm4ZTDl[oZm[3RiYXfhbY5{fCCndH;wc5Nq\GV? MXuyOlE3QTB5NR?=
HepG2 NImyWpdCeG:ydH;zbZMhSXO|YYm= MWGyNO69VQ>? MoX5NYg> NHTwNFhifHSnboXheIVlKHSqZTDhdI9xfG:2aXOgbY5lfWO2aX;uJI9nKEmLST2xNOKh NXSwTYlxOjZzNkS3PVU>
BEL-7402 Mn6xRZBweHSxc3nzJGF{e2G7 NHGxVlMzOM7:TR?= MnHCNYg> NVnoN4Q6[XS2ZX71ZZRm\CC2aHWgZZBweHSxdHnjJIlv\HWldHnvckBw\iCLSVmtNVDDqA>? MVeyOlE3PDd7NR?=
CEF M3jsWGtqdmG|ZTDBd5NigQ>? MYGwMFM{NDZ5LEGwNO69VQ>? NY[ye|dMOTWvaX6= Mm\k[I94di2{ZXf1cIF1\XNiUGKg[Y57gW2nIHHjeIl3cXS7IITvJFQx97zHIHH0JFExOM7:TR?= NWTpNJJCOjZzMEKzN|k>
SP2/0 NYD0dYNiSXCxcITvd4l{KEG|c3H5 M{mydVExOM7:TR?= MmXoNYg> Mn;LSG1UVw>? NYn0TY5Z[myxY3vzJJRp\SCjcH;weI9{cXNib3[gV3AzNzBiY3XscJM> NVnp[JhSOjZyN{S3N|I>
HUVEC-2c Mn7ORZBweHSxc3nzJGF{e2G7 NUPXc3VvPTEQvF2= NHHnZm03cA>? M1fxe4Rm[3KnYYPl[EB1cGVib4itUGRNNWmwZIXj[YQh[XW2b4DoZYd6 M4K0VVI3ODJzN{K5
U1 MYjBdI9xfG:|aYOgRZN{[Xl? NVfrO21VOC1zMEFOwG0> NGXq[2szcA>? NYTzO4s{emWmdXPld{BlenWpLXnu[JVk\WRiYYDvdJRwe2m|IHHu[EB{fWK|ZYH1[Y51KEiLVj2xJJJmeGyrY3H0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mlv4NlU6QDB7NEK=
ACH-2 MnLVRZBweHSxc3nzJGF{e2G7 M2[0XlAuOjByzszN NEHlZnEzcA>? NYL5ZXp4emWmdXPld{BlenWpLXnu[JVk\WRiYYDvdJRwe2m|IHHu[EB{fWK|ZYH1[Y51KEiLVj2xJJJmeGyrY3H0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVOyOVk5ODl2Mh?=
U1 M2nVWWtqdmG|ZTDBd5NigQ>? Mn\sNVAx|ryP NXKxWJltOmh? MUDpcohq[mm2czDjZZNx[XOnLUO= Mn6wNlU6QDB7NEK=
A549/V16 M2nlbmFxd3C2b4Ppd{BCe3OjeR?= MmDFOVDPxE1? MV[xbC=> NGO2fGxz\XC{ZYPz[ZMhXEdxVF2tbY5lfWOnZDDhdI9xfG:|aYO= MYqyOVk1PjB|Mx?=
SGN MljVRZBweHSxc3nzJGF{e2G7 MoXuNlBuVQ>? M1L3cFQ5cA>? MXroZZMhdm9iaX7mcJVmdmOnIH;uJGFKTixiY3HsdIFqdiCneIDy[ZN{cW:wIH;yJINmdGxiYYDvdJRwe2m| MkPFNlU5PzR4M{O=
HCT116  NGLNcJFCeG:ydH;zbZMhSXO|YYm= MmnvOVDPxE1? M2TMRlJp MnPqbY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiaX7keYNm\CCkeTDESHZR MYOyOVg3QDhzOB?=
DTK-SME M1f6fWFxd3C2b4Ppd{BCe3OjeR?= Mn;HOVDPxE1? MV:ybC=> MkjqSG1UVw>? M2jHbZBienSrYXzsfUBqdmirYnn0d{B1cGViYYDvdJRwe2m|IHnu[JVk\WRiYomgZpVxcX[jY3HpcoU> Mk[zNlU5PDN6OUe=
HL-60 MoHtRZBweHSxc3nzJGF{e2G7 NWXVZ|JqPTEQvF2= MV[0PIg> NWnoeGhuemWmdXPld{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCVS1mtTWkhfHKnYYTt[Y51yqB? M3z4T|I2QDJ2MESz
U937 NWDDRYxCSXCxcITvd4l{KEG|c3H5 MUe1NO69VQ>? MUe0PIg> NGTJfnNz\WS3Y3XzJINmdGxiZHXheIgh[2G3c3XkJIJ6KFONST3JTUB1emWjdH3lcpTDqA>? NFvLWVAzPTh{NEC0Ny=>
A549 M3TtOWFxd3C2b4Ppd{BCe3OjeR?= Ml;RNlAh|ryP M3\3fVI1cA>? MV3y[YR2[2W|IHPlcIwh\GWjdHigZ4F2e2WmIHL5JGhHS1BidILlZZRu\W62 MmfVNlU4QTRzNEm=
HeLa NXHpVZh5SXCxcITvd4l{KEG|c3H5 M3fRUFEx|ryP NELiWWE1QGh? MYTk[YNtcW6nczD0bIUhemG2ZTDv[kBieG:ydH;zbZMh\HKjbXH0bYNidGy7 M1rvUFI2Pzd{NUS1
SGC-7901 NXPseY1jSXCxcITvd4l{KEG|c3H5 M3q2UFIxyqEQvF2= M3\pdVFp NEXIUJhqdmirYnn0d{B1cGViY3XscEBl\WG2aDDpcoR2[2WmIHL5JI95[WyrcHzheIlv MlrFNlU4PjdyN{[=
MCF-7 NGDxOo5CeG:ydH;zbZMhSXO|YYm= NG\KZZkyOM7:TR?= MYKybC=> M4TxVYlvcGmkaYTzJJRp\SClZXzsJIRm[XSqIHnu[JVk\WRiYomgN2I> NF7TR5MzPTd{MkGxOC=>
A549 NWTCd|lKSXCxcITvd4l{KEG|c3H5 M1LUelExKM7:TR?= MmjENlRp MYPEUXNQ MmjPdJJwdW:2ZYOgTGJENXS{ZXH0[YQhSTV2OTDj[YxtKHO3co\peoFtKCZiYYT0[Y52[XSnczD0bIUh[2ynYY\l[EBRSVKSIHX4dJJme3Orb36= MnLnNlU3QDN3Nki=
U87 M2HRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXW1NO69VQ>? M333fFFp MVjy[YNwfmW{czDj[YxtKGe{b4f0bEBnem:vIGTNXkB1emWjdH3lcpQ> MnrWNlU3QDF4Nki=
Neocortical Neuron M4H4eG5mfXKxdH;4bYNqfHliQYPzZZk> MXSxNFDPxE1? NUTVe3ZJOWh? MXXhcpRi\2:waYrld{BJd2mjbXnk[UBCNUmwZIXj[YQhVmW3cn;0c5hq[2m2eR?= NX\pd206OjV4N{WwNFE>
Primary human placental cytotrophoblasts NIf4ZXVCeG:ydH;zbZMhSXO|YYm= NXPocZhROzEQvF2= M1;WeVI1cA>? M1;LS2ROW09? M3f5NJJmfmW{c3XzJJRp\SCrbnjpZol1cW:wIH;mJFEy|rJvSGPENkBjgSC2cnnjcI9{[W8EoB?= MoHDNlU3PDJ3OUK=
MM M364WmFxd3C2b4Ppd{BCe3OjeR?= MWG1NO69VQ>? NInsTHAzOG2rbh?= MmXndIFzfGy7IHnubIljcXS|IGPIT{1qdmS3Y3XkJEBk\WyuIHTlZZRp NFPEUWMzPTV|MEC5PC=>
DLD1 NIC5[olCeG:ydH;zbZMhSXO|YYm= M{TpTlIxyqEQvF2= NYe2OoRyOWh? MoLjdIFzfGy7IILleoVze2W|IHPlcIwh[XCxcITvd4l{KGOjdYPl[EBjgSCZU2Cx NYPGN|lZOjV3MkSyOFY>
MDA-MB-231 M2W4bWN6fG:2b4jpZ4l1gSCDc4PhfS=> M1vUc|Ex|ryP NIrEflAycA>? NHG2bmVifWevZX70d{Bk\WyuIHTlZZRpKGGodHXyJGNJXUFidILlZZRu\W62 NEnm[VAzPTV{MUWwNS=>
MKN28 M1r3UWFxd3C2b4Ppd{BCe3OjeR?= MnvPNVDPxE1? Mkm2N|BucW5? MnvZSG1UVw>? NGPIdpFqdmirYnn0d{BVVkZvzsGgdIx2eyCFSGitbY5lfWOnZDDhdI9xfG:|aYO= NEn5NWozPTVzM{m2NC=>
HL-60 Mm[0R5l1d3SxeHnjbZR6KEG|c3H5 NF74[mEyODEQvF2= M4rCOVFp MlTXSG1UVw>? NGLZb5jDqGmvcILveoV{KH[rYXLpcIl1gSCxZjDUR25Cey22cnXheIVlKGOnbHzz NVzMbWx2OjV3MEK5N|I>
AGS NULpT4pxSXCxcITvd4l{KEG|c3H5 NF;QXZcyOM7:TR?= MWKxbC=> NELTd2pxemW4ZX70d{BkfXKldX3pck1qdmS3Y3XkJINt\WG4YXflJI9nKGOjc4Dhd4UuOyxiLUisJIFv\CBvOTDwdo91\Wmwcx?= M2jYV|I2PDl{MkG0
A549  MmjnRZBweHSxc3nzJGF{e2G7 MYSxNO69VQ>? MYOyOIg> NFjiOY9jdG:la4OgSG1CWy2rbnT1Z4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDhcoQh[XCxcITveIlkKGOnbHyg[IVifGh? NF7iUVkzPTR|NEm4PS=>
INS-1 NV;Hd5NtSXCxcITvd4l{KEG|c3H5 Ml3kOVDPxE1? NVHt[5U1Pmh? NV3qZ2x6TE2VTx?= Ml7L[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIViemy7IHHwc5B1d3SrYzDj[Yxte8Li Mm[5NlU1OzB6OUe=
Primary hepatocytes  MXTBdI9xfG:|aYOgRZN{[Xl? Ml\4OVDPxE1? NYHCOnZlOTiq NVPPVXl2cW6qaXLpeJMh[XCxcITvd4l{KG:oIHjldIF1d2O7dHXzJIlv\HWlZXSgZpkhSWO2IFSgZY5lKFSQRj5OtS=> MmLXNlU1ODd3M{i=
L929-A  NH7xbWdEgXSxdH;4bYNqfHliQYPzZZk> MkjKNlDDqM7:TR?= MYSyOIg> NYXqdnJ6cW6qaXLpeJMhXE6IzsGtbY5lfWOnZDDj[YxtKGSnYYTo NGHRVpczPTN7OEW0NC=>
L929-N MWTDfZRwfG:6aXPpeJkhSXO|YYm= NGfRWpAzOMLizszN M4LDb|I1cA>? MWflcohidmOnczDk[YF1cCC4aXGgZZV1d2O{aX7lJHRPTs7zIIDyc4R2[3Srb36= MmLINlU{QTh3NEC=
Cytotoxicity Assay Ml7HR4VtdCCYaXHibYxqfHliQYPzZZk> NFyzVGczOM7:TR?= NGDsWHM1QGh? MWTwdoV3\W62IF3IUWQucW6mdXPl[EBk\WyuIHTlZZRp MVWyOVM6OjFzNh?=
COS7 MnLOT4lv[XOnIFHzd4F6 NF7vRnkyOM7:TR?= M4rF[FI1cA>? NYH5cYFKcW6lcnXhd4V{KGOjc4Dhd4UhOy95IHHjeIl3cXSrZYO= NIOxbYszPTN6NECyOS=>
COS7 NXPjT2dlSXCxcITvd4l{KEG|c3H5 NUHsXW5oOTEQvF2= NFH3dVM1QGh? MVXwZZJ1cWGubImgdJJmfmWwdHXkJGZEOTBzLXnu[JVk\WRiY3XscEBl\WG2aB?= NWDmT4R2OjV|OESwNlU>
A375 MlLXRZBweHSxc3nzJGF{e2G7 MXizNO69VQ>? NIC0ZVczcA>? NHvET3RxemW4ZX70d{B1cGViZIL1[{1qdmS3Y3XkJHBCWlBiY3zlZZZi\2V? MnyyNlU{PzZzMUW=
A549 Ml3RRZBweHSxc3nzJGF{e2G7 MnXQOVDPxE1? NYj0[2FjOjSq NYjZTFNnemW4ZYLz[ZMhemmkb4PvcYUh[mmxZ3Xu[ZNqeyCjbnSgZZBweHSxc3nzJINifXOnZDDifUAhS2iran;u[4Ridg>? MYmyOVM1QTd6MR?=
A549 NIjwfXRCeG:ydH;zbZMhSXO|YYm= MV:yMlUuOjYQvF2= MVSxbC=> NFXvfJhl\WO{ZXHz[ZMhfGinIIDvdJVt[XSrb36gc4Yh[XCxcITveIlkKGOnbHzzJIRmeGWwZDDvckBkd26lZX70doF1cW:wcx?= NHfTW5EzPTN2MkSyOy=>
 NBL-W-S  NYDDcGVvSXCxcITvd4l{KEG|c3H5 NY\JeopUPTEQvF2= M{DF[FFp NFfTUHFnfWyueTDy[ZNkfWW|IHPlcIwhfmmjYnnsbZR6KGGodHXyJGdCVlRvNkGgeJJm[XSvZX70 NEW0XZAzPTN{M{KyNi=>
Caki-1  NVrP[WJtSXCxcITvd4l{KEG|c3H5 NHfsdng1OM7:TR?= MXG0PIg> NIPtNIdz\WS3Y3XzJJRp\SCwdX3i[ZIhd2ZiQX7u[ZhqdiCYLYDvd4l1cX[nIHPlcIx{ MWKyOVI4QTF7MR?=
769-P MmDVRZBweHSxc3nzJGF{e2G7 NXHUcXdKPDEQvF2= MWi0PIg> NUPrZoR{emWmdXPld{B1cGViboXtZoVzKG:oIFHucoV5cW5iVj3wc5NqfGm4ZTDj[Yxtew>? NWi4SGl1OjV{N{mxPVE>
H9c2 NVXvNVZNSXCxcITvd4l{KEG|c3H5 M1ixdlUx|ryP NVHmToZnOWh? NVqxN412cW6qaXLpeJMhTE:[LXnu[JVk\WRiY3HzdIF{\SB|IHHjeIl3[XSrb36gZpV1KG6xdDD0bIUhdG:|czDv[kBk\Wyucx?= M3\TSVI2Ojh|OEG5
K562 NXXlPJBTSXCxcITvd4l{KEG|c3H5 NGHhbZM2OM7:TR?= M3v4e|Rp M1XzUIlvcGmkaYTzJGpi[y2DLXnu[JVk\WRiY3XscEBieG:ydH;zbZM> NF7aWWUzPTJ2MU[xPS=>
L929 MlnjRZBweHSxc3nzJGF{e2G7 MkTmNVDPxE1? MY[2bC=> MYTpcoR2[2W|IH7lZ5JweHSxc3nzJJdqfGhiVF7G NHnFSYUzPTF7NU[2NC=>
A549 MmTiRZBweHSxc3nzJGF{e2G7 MV6xNO69VQ>? MXuzbC=> NXn4O|JKemWmdXPld{Bk\WyuIHHwc5B1d3OrczDjZZV{\WRiYomgVHFS NF7QO24zPTF4MU[5PS=>
MCF-7 M4rDXmFxd3C2b4Ppd{BCe3OjeR?= NI\iSGQzOM7:TR?= MXWybC=> MlLP[IVkemWjc3XzJGtFWi2|aWLORU1qdmS3Y3XkJIFxd3C2b4Ppdy=> Mln2NlUyQDJ{NEC=
OS NFzVbYJCeG:ydH;zbZMhSXO|YYm= Ml;PNlAwPDEQvF2= MkT3O|Jp NFvNfFBqdmirYnn0d{BQWyClZXzsJJZq[WKrbHn0fUBz\WS3Y4Tpc44h[nliQ{[gZ4Vz[W2rZHW= NYnVSWtWOjVzNUKzPVk>
HUVECs MlzzRZBweHSxc3nzJGF{e2G7 MnvmNVDPxE1? M{X6dFJp MYdCpIlvcGmkaYTzJIFxd3C2b4Ppd{BidmRiZnHjbYxqfGG2ZYOgZZV1d3CqYXf5JIlvKESHTm[yMYlv\mWldHXkJGhWXkWFcx?= Ml;ONlUyOzh5MEO=
EA.hy926 MYfBdI9xfG:|aYOgRZN{[Xl? MmnnNVDPxE1? Ml7TNog> NYnHTFJPyqCrbnjpZol1eyCjcH;weI9{cXNiYX7kJIZi[2muaYTheIV{KGG3dH;wbIFogSCrbjDESW5XOi2rbn\lZ5Rm\CCHQT7ofVkzPg>? NVXtcoJPOjVzM{i3NFM>
Ebs MXLBdI9xfG:|aYOgRZN{[Xl? MofGNVAuOTByzszN MWeyOIg> MlfZxsBOVVSVIHflcoVz[XSrb36gdoF1\SCmZXPy[YF{\WRiYYOgeIhmKGOxbnPlcpRz[XSrb36gc4Yhgi2YQVSu[o1sKGmwY4LlZZNm\A>? MojpNlUyOzR6MUe=
Jurkat MlfzRZBweHSxc3nzJGF{e2G7 NY[3XJlROjEQvF2= M2ixOVI1cA>? Mn32SG1UVw>? MVTwZZJ1cWGubImgbY5pcWKrdDDj[YxtKGSnYYToJI9nKEq3cnvheEBk\WyuczDpcoR2[2WmIHL5JFExODV6LV[0JINwdWKrbnXkJJdqfGhiVmDBxsA> M2LpdFI2OTJyN{Kz
K562 NV7zR3dlSXCxcITvd4l{KEG|c3H5 NID3fHMxNjFvMd88US=> MUexbC=> M4HxfYlvcGmkaYTzJINt\WG4YXflJI9nKEiVUEmwJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NELyUoszPTFzOUG4PC=>
IMR-32 NEjLcXBCeG:ydH;zbZMhSXO|YYm= NFzadVY1OMLizszNxsA> MU[ybC=> MmCy[IVkemWjc3WgbY4h[XCxcITveIlkKGOnbHzzJINwdXCjcnXkJJRwKFRvMjD0c5hqdg>? MV:yOVA5PDd3NR?=
RPMI 8226 NIfqWFVCeG:ydH;zbZMhSXO|YYm= NVjPVFVjOTByzszN M1LIcVFp M4m2R4FtdW:|dDDjc41xdGW2ZXz5JIJtd2OtczDj[YxtKGSnYYToJINifXOnZDDifUBv\WO{b4P0ZZRqdi1z MYqyOVA{Pzh3MR?=
U266  NEPXXlNCeG:ydH;zbZMhSXO|YYm= MnW5NVAx|ryP NWTnfYNZOWh? NYXEbFF6eGG{dHnhcIx6KGKub3Prd{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCwZXPyc5N1[XSrbj2x MV2yOVA{Pzh3MR?=
H929  M2TWTWFxd3C2b4Ppd{BCe3OjeR?= Mo\2NVAx|ryP Mn7rNYg> M1PYZZBienSrYXzsfUBjdG:la4OgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhdmWlcn;zeIF1cW5vMR?= MnnhNlUxOzd6NUG=
MM.1S  MmnWRZBweHSxc3nzJGF{e2G7 MoriNVAx|ryP M1zlfVFp NV7vNHB4\W[oaXPp[Y51dHlicILleoVvfHNic3;yZYZmdmmkLXnu[JVk\WRiY3XscEBl\WG2aDDjc41jcW6nIIfpeIghdmWlcn;zeIF1cW5vMR?= NF;POpEzPTB|N{i1NS=>
C6 Mm\rRZBweHSxc3nzJGF{e2G7 NIGyRYQ2OM7:TR?= MX:0PIg> NV3EZXVQeHKndnXueJMhfGinIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJkh[2G3c3XkJIJ6KHC{ZXfu[Y5wdG:wZR?= NVHiRpAzOjVyMUO0O|k>
AGS MWfBdI9xfG:|aYOgRZN{[Xl? NXnESm5zPTEQvF2= MUWyOIg> NX7aRolU[WKxbHnzbJMh|rJvbHHwZYNpd26nLXnu[JVk\WRiY3XscEBl\WG2aDDhcoQhcW6qaXLpeIVlKGe{b4f0bC=> NIC4[YQzPTByOU[5PC=>
HeLa  MoruRZBweHSxc3nzJGF{e2G7 M3\qcFQx|ryP NXmwR2dNOjSq MWDpcohq[mm2czD0bIUhcW6lcnXhd4VlKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IIPpVm5HOTJz NYTjNXRZOjR7Mki2PFU>
THP-1  NVzUNWoySXCxcITvd4l{KEG|c3H5 M1mwd|Ex|ryP MkTPNYg> NEP0ZpVz\WS3Y3XzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEGOQT3TSHTDqA>? NFvkdIYzPDl{M{[1Ny=>
P815  M2PZWWFxd3C2b4Ppd{BCe3OjeR?= MkfaNVAxKML3TR?= M1TvVlEzcA>? MnTwSG1UVw>? M2Oxb4lvcGmkaYTzJJZqenW|LXnu[JVk\WRiYYDvdJRwe2m| MkXVNlQ6OjN{N{O=
HCT116 MlLiRZBweHSxc3nzJGF{e2G7 NGXXNVYzOM7:TR?= NGDMV4MzPGh? NWPSNG1o[WK{b3fheIV{KG:oIGTRMYlv\HWlZXSgZZBweHSxc3m= NGrZfnMzPDh7MES0PS=>
SW1116  M1LnUGFxd3C2b4Ppd{BCe3OjeR?= MmXBNVAhyrWP NGLNT4YycA>? M3K5[WROW09? NXfUN|gyemW|dILhbY5{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkh\2WoaYTpcoljKHCudYOg[IVkcXSjYnnu[S=> NEnGV5QzPDh5NEK4Oi=>
LOVO NEH6VVFCeG:ydH;zbZMhSXO|YYm= NV;XRnNoOTBiwsXN NIrvTmEycA>? M{\pSmROW09? NELjfYRz\XO2cnHpcpMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBo\W[rdHnubYIheGy3czDk[YNqfGGkaX7l NU\MV3BpOjR6N{SyPFY>
SNU449  MVfBdI9xfG:|aYOgRZN{[Xl? MkfNNlDPxE1? NXvYb|VuPDiq MXTEUXNQ NIrpbW9l\WO{ZXHz[ZMhdWmULUS1NU1qdmS3Y3XkJIFxd3C2b4TpZy=> MlnmNlQ5PDF4M{i=
Caco-2 NELuZpBCeG:ydH;zbZMhSXO|YYm= MVK0NQKBkc7:TR?= NUTMToo1PGh? M37SZpBz\X[nboTzJHNVNTdvaX7keYNm\CCcTz2xJINp[W6pZYOgZY5lKFSHUjDkdo9x M4DPNFI1QDJ{MUiz
macrophage MWfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHz6eHIxNTJyMN88US=> MUCyOIg> MmHJbY5lfWOnczDUUmYuKGGwZDDSbZA{NWSncHXu[IVvfCCwZXPyc5B1d3OrczDpckBu[WO{b4DoZYdm NV6wdppvOjR5OUm1OlU>
AGS  Ml:3RZBweHSxc3nzJGF{e2G7 MlnYNlDPxE1? M4OzOVEzcA>? NVnTPZhjTE2VTx?= NWi2WFVJemWmdXPld{B1cGViaX7keYN1cW:wIH;mJIFxd3C2b4Ppd{BqdiC{ZYPwc45{\SC2bzD0bIUhTXSRQXOg[pJi[3Srb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M2HMW|I1Pzh7N{Cz
LCC9  NFe5NZpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2LrdFExOM7:TR?= MoLvOYQ> MojaZoxw[2u|IHPlcIwh\GWjdHigbY5lfWOnZDDifUBkd22kaX7heIlwdiCOMUegZY5lKGOqbH;yc5F2cW6n NYHPO|NMOjR5OEWyOVY>
U937  NFnSfmxv\WO{b4D0c5NqeyCDc4PhfS=> M{O2c|ExyqEQvF2= NGXvWmE{OMLibXnu NXq2em1NcW6mdXPld{Bv\WO{b4D0c5NqeyClb33ibY5mKHerdHigWG5H NEXVOmgzPDd5M{e1Oi=>
T cell Ml\QR4VtdCCycn;sbYZmemG2aX;uJIF{e2G7 MUiwMVExOM7:TR?= M4WwWFczcA>? M13pdGlEPTB;N{Cg{txONCCrbnjpZol1eyCjboTpMWNFOy2rbnT1Z4VlKFRiY3XscEBxem:uaX\ldoF1cW:wIHnuJHBDVUO| NHrVcYczPDd4OEewOy=>
HeLa  NXLwco41SXCxcITvd4l{KEG|c3H5 MkHDOVDPxE1? MkPMO|Jp MojDSG1UVw>? NWq4ZlZWeHKndnXueJMh[XCxcITvd4l{KGmwZIXj[YQh[nliY3;tdI92dmS|wrCx5qCUPQ>? NUfmfmt1OjR5NUS3PFY>
HeLa  NHvmT4VCeG:ydH;zbZMhSXO|YYm= NELLb3MyODEQvF2= M3rGb|I1cA>? M1nuTJN2eHC{ZYPz[ZMhemG2ZTDv[kBk\WyuIHTlZZRpKGmwZIXj[YQh[nlib4\ldoV5eHKnc4Ppc44hd2ZiR{W5V{BweiCJN{HSJJAyPTCpbIXl[OKh NUDaV2c4OjR5MkK0Olg>
IEC-6  NFG3d4RCeG:ydH;zbZMhSXO|YYm= MmLLNVDPxE1? MVWyOIg> NFzJV5lxemW4ZX70d{BV[2SDLXnu[JVk\WRiY3HzdIF{\S1|IHPs[YF3[WenIHHu[EDPui2lYYTlcolvKGSnZ4Lh[IF1cW:w M2\O[|I1PzFzNUex
HCT116 MljORZBweHSxc3nzJGF{e2G7 MXOyNO69VQ>? M164fVI1cA>? NFz5R29qdmirYnn0d{B1cGViY3XscEBieG:ydH;0bYMhcW6mdXPl[EBjgSC\TGSyNFU> MWGyOFcyOzhzMh?=
L02 MXrBdI9xfG:|aYOgRZN{[Xl? MWOyNO69VQ>? MXGxbC=> NXrUWJA5eHKndnXueJMhfGinIHPlcIwh[XCxcITvd4l{KGmwZIXj[YQh[nliTVXIVC=> M4e0[VI1PzB4NE[x
A375 MVzBdI9xfG:|aYOgRZN{[Xl? MUGyNO69VQ>? MV:yOIg> Mne2doV3\XK|ZYOg[IlkcXS{aX7vcoUhSi2rbnT1Z4VlKGGyb4D0c5Nqew>? NV;QW20zOjR4OUmxNVE>
HDPC NULGdIF[SXCxcITvd4l{KEG|c3H5 MV21NOK2VQ>? M4G5[lI1cA>? M{nIXolvcGmkaYTzJG5QNWmwZIXj[YQh[XCxcITvd4l{ MkXiNlQ3OzR3OUO=
A549 MknmRZBweHSxc3nzJGF{e2G7 M{nMTVUxyrWP MmDhNog> MnqwSG1UVw>? M{\XfJBz\X[nboTzJJRp\SCqeYDv[IlxdG:rZDDEUmEh[2:wdHXueEBxcGG|ZTDpcoR2[2WmIHL5JINmeGijbH;jbJJwdWmw NW\HfXpxOjR3OEixN|U>
 BV-2 NHftW4NCeG:ydH;zbZMhSXO|YYm= M2XhT|Ix|ryP M1L4ZlJp MVjzeZBxemW|c3XzJHVXNWmwZIXj[YQh[2i{b33heIlvKGW6dIL1d4lwdiCjbnSg[Ilt[XSrb36gc4YhfGinIH71Z4xm[XJiZX72[YxweGV? M1rJb|I1PTV6MUG4
HT-29  NVfrcYJPSXCxcITvd4l{KEG|c3H5 MlL4OVDPxE1? MXy0PIg> M1;PcYJtd2OtczD0bIUh[XCxcITvd4l{KGmwZIXj[YQh[nlia3HlcZBn\XKxbB?= MWqyOFU1QTF5NR?=
A549 MkD5RZBweHSxc3nzJGF{e2G7 M2nHclXPxE1? MoKzNlRp MonKd5VxeHKnc4Pld{A3\cLiKFLLNVAxPDBrLXnu[JVk\WRiYYDvdJRwe2m|wrC= NYLx[5RuOjR3Mkm4O|E>
MIA-PaCa-2 NH7ofZFCeG:ydH;zbZMhSXO|YYm= MV2yOIg> NYXPTlFN[myxY3vzJINt\WG4YXflJI9nKGOjc4Dhd4UuOyCrbnT1Z4VlKGK7IHLveIghSS12NEO2OVQh[W6mIIDhZ4xqfGG6ZXy= M1TNOVI1PTFyOUmy
Caki-1 MVHBdI9xfG:|aYOgRZN{[Xl? MlKzNlDPxE1? MYKxbC=> NGLpZVhqdmirYnn0d{BUS1BvaX7keYNm\CCjcH;weI9{cXN? NWPBVItZOjR3MES2PFE>
CLL NUn0TWYySXCxcITvd4l{KEG|c3H5 NXz5VVJOOjYQvF2= NGPNV2gycA>? MUjwZZJ1cWGubImgZoxw[2u|IF3MUlIzOzhvaX7keYNm\CClZXzsJIFxd3C2b4Ppdy=> Mlz5NlQ1Pjd4M{S=
SGC-7901 M{nadmFxd3C2b4Ppd{BCe3OjeR?= NXTLNGFoOTEQvF2= MnrvNlRp NVHkd3lQeHKxbX;0[ZMhfGinIFPHTWkucW6qaXLpeIVlKGOnbHyg[5Jwf3SqIHnuJHNISy15OUCxJINmdGy| MVmyOFQ2PDR6OB?=
k1735 MmnNRZBweHSxc3nzJGF{e2G7 MkXhNlDjiIoQvH2= MUG0bC=> NGC0VHlqdmirYnn0d:KhW2GubX;u[Yxt[S2rbnT1Z4VlKGGyb4D0c5Nqew>? NIK1TmIzPDR3MUGxOi=>
HaCaT  NInsSnRCeG:ydH;zbZMhSXO|YYm= Mn\SNVAx|ryP MWmxbC=> M3;w[YJtfW62czDVWmIucW6mdXPl[EBieG:ydH;zbZMhcW5iSHHDZXQh[2WubIO= NV3GPXJ4OjR|NU[5PVc>
podocytes MnztRZBweHSxc3nzJGF{e2G7 NETXS2czODEQvF2= M3rwPFZp NV;uUFBPcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliMzy0MWRITQ>? NIrsRmczPDN|N{e3Oy=>
 KB NYrjbZhJSXCxcITvd4l{KEG|c3H5 MkfVOVDPxE1? Mmr6NlRp MYDpcohq[mm2czDMbYNwNUFvaX7keYNm\CClYYPwZZNmNTNiYX7kJHBCWlBiYXP0bZZifGmxbh?= NEW0cpkzPDN|N{S5Ni=>
 HepG2  MWfBdI9xfG:|aYOgRZN{[Xl? NH3ZTXMyOM7:TR?= Mn\pNlRp M1TSWZJm\HWlZYOgeolu\W62aX6gZ4xm[X[jZ3WgZ4F2e2WmIHL5JGxRWw>? M37mV|I1OzJ3OEG2
fetal rat lung fibroblasts  MlHBT4lv[XOnIFHzd4F6 MUK4NO69VcLi NHv3VpUycA>? MULpcohq[mm2czDDZZNx[XOnLUOgZYN1cX[rdIpCpC=> Mnr3NlQ{OTRzM{W=
PDL fibroblasts NXHr[pJKU2mwYYPlJGF{e2G7 NGPJVYc5OM7:TdMg NGKzb3QycA>? NVvhS5ZmcW6qaXLpeJMhS2G|cHHz[U0{KGGldHn2bZR6yqB? NEixfnAzPDNzNEGzOS=>
MB49 NH\nd3NCeG:ydH;zbZMhSXO|YYm= MVWyNO69VQ>? MkLoNYg> NF3SUoxz\X[ncoPld{BEVS2rbnT1Z4VlKGOnbHyg[IVifGh? NUW3Z|huOjR{OEK0N|M>
5637 NX3XOZJMSXCxcITvd4l{KEG|c3H5 MkHzNlDPxE1? NW[0d|R4OWh? NUHF[lJpemW4ZYLz[ZMhS01vaX7keYNm\CClZXzsJIRm[XSq M4\IXlI1Ojh{NEOz
A549  NYK0XpdsSXCxcITvd4l{KEG|c3H5 M2jnOVExOM7:TR?= MoDiOFhp M2S2TZN2eHC{ZYPz[ZMhfGinIHHwc5B1d3OrczDjZZV{\WRiYomgdIlx\XKrbnZCpC=> MoPBNlQzPzJ{MEG=
MCC-2 MoLKRZBweHSxc3nzJGF{e2G7 NUX1fW1rOjBizszN MkDzOog> NYrhPHhqTE2VTx?= NFi5PIRjdG:la4OgbY5lfWOnZDDifUB{fGG3cn;zdI9zcW6nIHHwc5B1d3OrczDj[YxtKGSnYYTo NXrDWZlQOjR{NkK2OVg>
ADF NI\RXnBCeG:ydH;zbZMhSXO|YYm= NWLrS251PDEQvF2= NVnYW5hOPmh? M37tcYlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGOqZX3veIhmemGyeTDwcJV{KFqwQ3yy NX7SSJViOjR{MkiyN|I>
 U373  MULBdI9xfG:|aYOgRZN{[Xl? NGrEZ4M1OM7:TR?= NE\5UIg3cA>? M4LoU4lvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGOqZX3veIhmemGyeTDwcJV{KFqwQ3yy M2[1TVI1OjJ6MkOy
RKO-HIPK2i MVnBdI9xfG:|aYOgRZN{[Xl? Mnr5OFDPxE1? M{\DOFZp NWrWVFRFcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliY3jlcY91cGW{YYD5JJBtfXNiWn7DcFI> MUCyOFIzQDJ|Mh?=
HEC-1B MkG0RZBweHSxc3nzJGF{e2G7 MVGyNO69VQ>? MkPhNYg> MmXZdoVlfWOnczDUVE1qdmS3Y3XkJIFxd3C2b4Ppd:Kh[2G|cHHz[U0{KGGwZDDjZZNx[XOnLUm= NWrMe|BoOjR{MUOzOVg>
4T1 NIHyUW1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? MX2yMlUuOTEQvF2= MkWxOIg> MkO4SG1UVw>? MlLtdoV{[3WnczD0bIUh[3m2b4TvfIlkcXS7IH;mJFRVOSClZXzsd{BqdmS3Y3XkJIJ6KFOSRGSgbY4h[SClb37j[Y51emG2aX;uJIRmeGWwZHXueEBu[W6wZYK= M2\CSVI1OjB4MU[x
OS  MUjBdI9xfG:|aYOgRZN{[Xl? MXmyNO69VQ>? MWS0bC=> M3LXVolvcGmkaYTzJJRp\SClZXzsJIRm[XSqIHPheZNm\CCkeTDQSHQ> M1ftRVI1OjB2OUO3
RPE NW\4PVR2SXCxcITvd4l{KEG|c3H5 MX[xNFDPxE1? NGDSRWg1QGh? M3jFe5BienSrYXzsfUBqdmirYnn0d{B1cGViY3HsdIFqdi1zIHHu[EAuOiCjY4TpeoF1cW:wIHHzJJdmdGxiYYOgeIhmKGOjc4Dhd4Uh[WO2aY\heIlwdg>? M2jne|I1OjB{MEWy
UD29a MYfBdI9xfG:|aYOgRZN{[Xl? NWXieWFRPTEQvF2= M1\2NlI1cA>? NFvjTYFqdmirYnn0d{B1cGViY3XscEBl\WG2aDDjZZV{\WRiYomgUnVVOw>? MYGyOFE6ODV5NB?=
SH-SY5Y  M2TXbWFxd3C2b4Ppd{BCe3OjeR?= MnmzNVDPxE1? M3;adVI1cA>? MorQZZR1\W63YYTld{Bk[XOyYYPlJIFkfGm4YYTpc44h[W6mIHPlcIwh\GWjdHigbY5lfWOnZDDifUBJVkVvMlTH NX7CNZdDOjRzNEW0OlM>
HeLa  MWLBdI9xfG:|aYOgRZN{[Xl? NYTVR4sxOTBxMkFOwG0> NYfJRlFIOjSq NYDuUZZKcW6qaXLpeJMhfGinIHHjeIl3cXS7IH;mJJRp\SCvYXrvdol1gSCxZjD0bIUhdWWvYnXyd{Bw\iC2aHWgZ4F{eGG|ZT3mZY1qdHl? M1f2Z|I1OTN5Mk[2
SCCVII  NEDrSJlCeG:ydH;zbZMhSXO|YYm= MWiyOe69VQ>? MmjmNYg> M4PqOIlvcGmkaYTzJJRp\SClZXzsJItqdGyrbnegZYZ1\XJiZHHzZZRqdmmk NW[xZoRwOjRzMk[0OlQ>
RAW 264.7 MVjBdI9xfG:|aYOgRZN{[Xl? MlnMNlDPxE1? M{DyWVE5cA>? NF\pPFRqdmO{ZXHz[ZMhVEN|LVnJM:6zNWGldHnuJJJifGmxIHPvcZBiemWmIITvJGVEXFZvTV;TJJRz\WG2bXXueEBwdmy7 Mn63NlQyOTZ5MEe=
A549  NYTQdWN{SXCxcITvd4l{KEG|c3H5 NEHMOJAzNjYQvF2= MoHXNlRp MoPI[IVkemWjc3XzJI9zcWSxbnnuMYlv\HWlZXSgZZV1d3CqYXf5JIF{KHenbHygZY5lKEyxc4Ogc4Yh|pURiH2gZYx{dyCxY3P1dpJm\CCmdYLpcoch[XW2b4DoZYdq[yCycn;j[ZN{ M2[3WlI1OTB{NUKy
UM-SCC-10A  NYrLXXV{SXCxcITvd4l{KEG|c3H5 NUnRWIhuPTEEtV2= M4T1N|Jp M2raPZJm\HWlZYOgZZBweHSxc3nzJIlv\HWlZXSgZpkhcGmpaD3kc5NmKGm|b3HsZY51d2yjY4TvcoU> MmfJNlQxQTh5NUO=
BGC-823 M{TjTGFxd3C2b4Ppd{BCe3OjeR?= MXqxNEDPxE1? NEnqO3UzPGh? M3Wx[JJm\HWlZYOgeIV1emGwZILpcoUucW6mdXPl[EBieG:ydH;zbZPDqA>? MYCyOFA6QDVzMR?=
Nalm-6  M1f5cGFxd3C2b4Ppd{BCe3OjeR?= MYqyNO69VQ>? NWnVS5dqPGh? MW\pcohq[mm2czDjZZNx[XOnLUigZY5lKGOjc4Dhd4UuOyCjY4TpeoF1cW:wIHHu[EBRSVKSLUGgZ4xm[X[jZ3W= MmLCNlQxOzl7Nke=
KHOS  MoCwRZBweHSxc3nzJGF{e2G7 M4Lr[VQx|ryP NH;0NmkzPGh? MoL6Zoxw[2u|IITo[UBqdmO{ZXHz[YQh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|IHHu[EBRSVKSIHnu[JVk\WRiYomgRmJOTDQEoB?= Mn7KNlQxOjV|NkG=
G292 MoLMRZBweHSxc3nzJGF{e2G7 MoXuOFDPxE1? NWXkNlE1OjSq M2XjZoJtd2OtczD0bIUhcW6lcnXhd4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDpcoR2[2WmIHL5JGJDVUR|wrC= Mn6wNlQxOjV|NkG=
MG-63 NH:4TW5CeG:ydH;zbZMhSXO|YYm= MWi0NO69VQ>? NF3F[IQzPGh? M2HEcYJtd2OtczD0bIUhcW6lcnXhd4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDpcoR2[2WmIHL5JGJDVUR|wrC= NULXcZZ1OjRyMkWzOlE>
EBV-transformed B cells MV\BdI9xfG:|aYOgRZN{[Xl? MVmyNO69VQ>? NGPXVo8zcA>? Ml;LSG1UVw>? NGHNWGpjdG:la4OgZY51cS2FREiwJIFv\CCjboTpMWNFQDZiYX70bYJw\HlvaX7keYNm\CCjcH;weI9{cXN? NVj1dodMOjRyMEi2Nlg>
IM-9 B M{PWO2Fxd3C2b4Ppd{BCe3OjeR?= NUP3OIhGOjEQvF2= NV\oUJlPOmh? NF7Q[XJFVVOR M2HDSYJtd2OtczDhcpRqNUOGOECgZY5lKGGwdHmtR2Q5PiCjboTpZo9lgS2rbnT1Z4VlKGGyb4D0c5Nqew>? MlG2NlQxODh4Mki=
CNE1 Ml3XRZBweHSxc3nzJGF{e2G7 NUSxSXdHOjEQvF2= MoGyOFhp NUHLVXBL[myxY3vzJGxMNUFvaX7keYNm\CCjcH;weI9{cXN? NX72ZpA6OjN7OEWwNlk>
CNE2 NF\ve2ZCeG:ydH;zbZMhSXO|YYm= M4faUlIx|ryP NVLIdnFbPDiq M2q0PYJtd2OtczDMT{1CNWmwZIXj[YQh[XCxcITvd4l{ MlrWNlM6QDVyMkm=
HL-60 MVPBdI9xfG:|aYOgRZN{[Xl? MYm1NOK2VQ>? M4jkVlFp MkPDSG1UVw>? Ml\XbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhSkFzNEW= MlfTNlM6PDh5NUG=
L929 MX\BdI9xfG:|aYOgRZN{[Xl? MXWxMlI26oDVNdMg{txOyqB? NXLiXWpXOjSq MoPhZZVodWWwdIOgWG5H|rFvaX7keYNm\CCwZXPyc5B1d3OrczDhcoQh[XW2b4DoZYd6 M4HWflI{QTRzN{[5
Jurkat M2GybWNmdGxiVnnhZoltcXS7IFHzd4F6 MnvLNu69VQ>? NYDvdpZUPGh? MXry[ZZmenOnczDndo94fGhiaX7obYJqfGmxbjDhcoQh|rJvY3H0[Y5qdiCmZXPy[YF{\SCkeTDIV{1CW0F? MXKyN|g6PjB4MR?=
RAW264.7  NGLYOXZCeG:ydH;zbZMhSXO|YYm= M4\hRlExKM7:TR?= MYCyOIg> M3fLWYRm[3KnYYPld{B1cGViYYDvdJRwe2m|IHnu[JVk\WRiYomgS2E> NVzOfY5XOjN6MkCyNFM>
A431  MUfLbY5ie2ViQYPzZZk> M3LBTlQx|ryP MlLBNog> MkPwZoxw[2u|IH\pd4V1cW5vaX7keYNm\CClbHXheoFo\SCxZjDjZZNx[XOnczDhcoQhWEGUUB?= M{n5[|I{QDByMEW4
Jurkat NUPaRZFrS2WubDDWbYFjcWyrdImgRZN{[Xl? MU[yOU0yODEQvF2= MYW2bC=> NY\ZW2J6cW6qaXLpeJMhgi2IQT3DUWsucW6mdXPl[EBk\WyuIHTlZZRp MU[yN|k{OzV|Mh?=
COS-7  NVrtVVRxTnWwY4Tpc44hSXO|YYm= NFTyZmg2OML3TR?= NH7WUGczPGh? NYDGSmxx[W[oZXP0d{B1cGVicILvZ4V{e2mwZzDv[kBCXE5zczD3bZRpKHCxbInRJJRz[WO2cx?= MYWyN|k{OzJyOB?=
CAL27 M2L5[mFxd3C2b4Ppd{BCe3OjeR?= NHfHXmUyOCEQvF2= NIeyPFgzcA>? NEnRWGx{fXCycnXzd4V{KEO3cj3OVJMuemWmdXPl[EB3cWGkaXzpeJkh[nlidYCgeI8hQTBn NHvsZ3AzOzlzN{O5Oi=>
THP-1  NH\aWW5CeG:ydH;zbZMhSXO|YYm= M33NZ|ExNTVyzszN Mm[4Nog> NHn2U5dqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSC2cnnweI9tcWSn NG\ZV2QzOzlyMEK5PS=>
K562 MoHXRZBweHSxc3nzJGF{e2G7 MV:yNO69VQ>? MlL5OFhp M1rpTolvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KDRvTWW= NHfCfJEzOzh5NkiyOi=>
HL-60 M1jzUGFxd3C2b4Ppd{BCe3OjeR?= NGP0fZYyODEQvF2= MYiyOIg> M1nZNYlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGGkaXX0ZY5mKGSrdHXydIVv\XQEoB?= NVXXdZFWOjN6NkW3O|g>
HeLa  NVr6fFB3SXCxcITvd4l{KEG|c3H5 NXz0Z2Q6OjEQvF2= NHvWN5czcA>? Mn;xbY5pcWKrdIOgSG1OWCCrbnT1Z4VlKGGyb4D0c5Nqew>? NEHUcJMzOzh4M{m2Oi=>
U251 MXjBdI9xfG:|aYOgRZN{[Xl? NG\YUmozOM7:TR?= MWCyOIg> M2jnc4lvcGmkaYTzJINie3SrY3nuJIlv\HWlZXSgS|IwVSCyaHHz[UBienKnc4SgZY5lKGGyb4D0c5Nqew>? MljtNlM5OTZ6MU[=
HL-60 MWfBdI9xfG:|aYOgRZN{[Xl? NHvPNII2OML3TR?= NGrsPFA1cA>? M33NW4Jtd2OtczD0bIUh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|LDCtPUwh[W6mIGDBVnAhcW6mdXPl[EBjgSB4cx?= M4PJb|I{QDB2N{C2
Ec-109 MWXBdI9xfG:|aYOgRZN{[Xl? NEHuUocyOCEQvF2= MXG0PIg> MXfy[ZBz\XO|ZYOgVGUudWWmaXH0[YQhTWNvMUC5JINmdGxiYYDvdJRwe2m| MnPUNlM4QDJ4NEG=
RKO NGD0dVhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2\YelExKM7:TR?= MXOyOIg> MX;pcohq[mm2czD0bIUh\GWlcnXhd4Uhd2ZiY3XscEB3cWGkaXzpeJkh[2G3c3XkJIJ6KESDQh?= NX61T3ZJOjN5NUiwOlQ>
T98G NXm4dXpZS2WubDDWbYFjcWyrdImgRZN{[Xl? M3PXWlEuOTByzszN MUKyOIg> MmPYbY1xem:4ZYOgZ4VtdCC4aXHibYxqfHliY3;0doVifG2nboSge4l1cCCWUx?= NYr1TWV4OjN5NkmyO|U>
Jurkat MW\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXKxNFAuOjByzszN MVqyOIg> M4nqPIlvcGmkaYTzJGhiSTRiaX7keYNmeyCjcH;weI9{cXNiZHXw[Y5l\W62IH;mJINwdmOnboTyZZRqd28EoB?= MYOyN|c{OjR6MR?=
Molt-3  MYDBdI9xfG:|aYOgRZN{[Xl? MnjkOVDPxE1? MW[ybC=> NF;KOW5z\WS3Y3XzJI1mdGG2b37pck1qdmS3Y3XkJIFxd3C2b4Ppdy=> MlTRNlM4OjVyMUO=
hMSC12 M1rRbmFxd3C2b4Ppd{BCe3OjeR?= MkjGNVAx|ryP MYe0[C=> MlnwbY5pcWKrdIOgc5N1\W:pZX7pZ{BkfWy2dYLlMYlv\HWlZXSgZ4VtdCCmZXH0bEBidmRiY3HsZ4lncWOjdHnvci=> NFrGWY4zOzZ3N{iyNi=>
HM7  NWPlTZlYSXCxcITvd4l{KEG|c3H5 MnHaNlDPxE4EoB?= MoXRNYg> M3\3fIJtd2OtczDhdIlkfWyjcnXuJGEh[WOndHH0[U1qdmS3Y3XkJINie3Cjc3WtN{Bi[3SrdnH0bY9vKGGwZDDQRXJRKGOuZXH2ZYdm M2L3blI{PTh|NEGy
Hep-2  NEnTVlVCeG:ydH;zbZMhSXO|YYm= MUKyNO69VcLi M2r5dVI1cA>? MkXCSG1UVw>? MYHhcIxmfmmjdHXzJJRp\SCmZXPy[YF{\SCxZjDj[YxtKH[rYXLpcIl1gSCrbnT1Z4VlKGK7IIPpcIljcW6rbh?= NFO0eW4zOzV6MECzNi=>
HSCs MlLzRZBweHSxc3nzJGF{e2G7 MX[1NO69VQ>? NGnLO5czPGh? M4O1SGROW09? NUPJboJmcW6qaXLpeJMhdmmub4TpcoljNWmwZIXj[YQhTE6DIHThcYFo\SCrbnTpZ4F1\WRiYomgVGFTWCClbHXheoFo\Q>? MUCyN|Q6QTh5NB?=
HL-60  NWSxWHltS3m2b4TvfIlkcXS7IFHzd4F6 MYeyNO69VcLi M4nvTFI1cA>? NYjyWWxmemWmdXPld{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDFdpk2 M1;YWVI{PDl2NEiw
HA M4\zdmFxd3C2b4Ppd{BCe3OjeR?= MXG1NO69VQ>? NWnXPIMxOjSq M3zhOZN2eHC{ZYPz[ZMhfGinIHPs[YF3[WenIH;mJHBCWlBiYX7kJINie3Cjc3WtN{whNTduIHHu[EAuQSCrbnT1Z4VlKGK7IHLvdpRmgm:vaXKvV2FJSQ>? NWjIfJh3OjN2N{W5OVY>
C666-1 Mlj1RZBweHSxc3nzJGF{e2G7 M3fmZVUx|ryP MkPaNlRp NGe4cVd{fXCycnXzd4V{KHSqZTDjcIVifmGpZTDv[kBRSVKSIHHu[EBk[XOyYYPlMVMtKC15LDDhcoQhNTliaX7keYNm\CCkeTDic5J1\XqxbXniM3NCUEF? NFe0NHozOzR5NUm1Oi=>
Hepa1-6 MXjBdI9xfG:|aYOgRZN{[Xl? NXnIc3V3PTEQvF2= NXfaXGd1Omh? NFfoRlNqdmirYnn0d{BkfXKldX3pckBidmRicnXzeoVz[XS{b3ytbY5lfWOnZDDhdI9xfG:|aYO= NGC1TFAzOzR2Nke1Ny=>
PLC/PRF/5c MnnYRZBweHSxc3nzJGF{e2G7 NFPQRXU2OM7:TR?= MXGxbC=> MWXwdoV3\W62czDhdI9xfG:|aYOgeJJq\2encnXkJIJ6KEOLTh?= NGHkc4wzOzR|OEiyOC=>
HCT116 Ml\5RZBweHSxc3nzJGF{e2G7 MWGxNFDPxE1? M2O5dFEvPWh? M{e3NYlvcGmkaYTzJG9{NWmwZIXj[YQh[2WubDDk[YF1cA>? MYmyN|c1PDN3Mx?=
HCEC M3TZOGZ2dmO2aX;uJGF{e2G7 M{\LZ|Ux|ryP NYLTPXl1PzKq MULEUXNQ NGnn[lNz\XO2b4Lld{Bw\iC2aHWgco9zdWGuIFjDSWMheGinbn;0fZBm NYDSPGZUOjN5NEKwNVE>
Primary rat cerebral cortical neurons MWHBdI9xfG:|aYOgRZN{[Xl? MkOxNVAx|ryP NGrGd2kycA>? MX7wdoV3\W62czDD[E1qdmS3Y3XkJIFxd3C2b4Ppd{BidmRiY3XscEBl\WG2aB?= M3qyS|I{PzRzM{G3
MDA-MB-231  MXfBdI9xfG:|aYOgRZN{[Xl? M375ZlI2|ryP MYGyOIg> NWK4Z|Vu[WK{b3fheIV{KGO7dH;0c5hq[2m2eTDhcoQh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|IHHu[EBRSVKSIHnu[JVk\WRiYomgVoc{ M2LwTlI2OzN5NUS0
NLRP3-Tet-on-MC/9  MofNRZBweHSxc3nzJGF{e2G7 NWLCbGpYOTBvNEFOwG0> NICzRZEyOmh? MXrheJRmdnWjdHXzJJRp\SClZXzsJIRm[XSqIHPheZNm\CCkeTDDRXBUNWG|c3;jbYF1\WRiTlzSVFMhdXW2YX70d{BqdiC2aHWgWIV1NW:wIIP5d5RmdQ>? NYO0XWU6OjN5MEOzPFk>
KNS42  NV\tcVNnSXCxcITvd4l{KEG|c3H5 NVjaUoFPPTEQvF2= M3jpZVFp NGr6d3Jz\WS3Y3XzJINmdGxiZHXheIgh[W6mIHPvcZBt\XSnbImgZYJwdGm|aHXkJINie3Cjc3WgN{84KGGldHn2bZR6KGmwIILld5BwdnOnIITvJGFDXC1{NkOvNmRIN22ndH\vdo1qdiClb33ibY5ifGmxbh?= MUmyN|Y6OTF2NR?=
MCF-7  MkPJRZBweHSxc3nzJGF{e2G7 MUCyNO69VcLi MnfqO|Jp MXHpcohq[mm2czDldZVwdC1iYX7kJFQuV0iWLX3l[IlifGWmIHHwc5B1d3Orcx?= NHTDT3kzOzZ5NU[0Ny=>
hCMEC/D3  M1PKR2Fxd3C2b4Ppd{BCe3OjeR?= MWSyOe69VQ>? MVS3Nog> MX;y[YR2[2W|IFz0fGEhcW6mdXPl[EBieG:ydH;zbZM> MXKyN|Y3PTF7OB?=
Jurkat Mmf2RZBweHSxc3nzJGF{e2G7 M4rOOFEzNjVvNUFOwG0> NU\WdIY4OWh? NVKzNGp{\G:|ZTDk[ZBmdmSnboTsfUB{fXCycnXzd4V{KFOSSD3pcoR2[2WmIGDhdk01KGOuZXH2ZYdmNCCSQWLQJINt\WG4YXflMEBFVkFiZoLh[41mdnSjdHnvckwh[W6mIHzvd5Mhd2ZidnnhZoltcXS7 MnLLNlM1PDJ7N{[=
CNE-1 MVrBdI9xfG:|aYOgRZN{[Xl? NFjQeIozOM7:TdMg NV;YNIJGOjSq MknIbY5pcWKrdIOgVmFFODBzLXnu[JVk\WRiY3XscEBl\WG2aB?= NGHUNFIzOzR{Nki1NC=>
HONE-1 MlnPRZBweHSxc3nzJGF{e2G7 Mny0NlDPxE4EoB?= MXmyOIg> NITDbJdqdmirYnn0d{BTSURyMEGtbY5lfWOnZDDj[YxtKGSnYYTo MVeyN|QzPjh3MB?=
astrocytes cell NIW1WIdCeG:ydH;zbZMhSXO|YYm= NHHTbYw1OM7:TR?= MWC2bC=> M3;pdpJm\HWlZYOg[YFzdHliYYDvdJRwe2m|IHnu[JVk\WRiYomgd5RifXKxc4Dvdolv\Q>? NFTNb|QzOzRzMUe3PC=>
U-937 Mom2RZBweHSxc3nzJGF{e2G7 NYixbHk2OTEQvF2= NXTnfIZXOzCvaX6= NFHNe5BxemW4ZX70d{BVVkZvaX7keYNm\CCwZXPyc5B1d3Orcx?= MWCyN|QyODd2OB?=
MDA-MB-231 NX3YSZRWSXCxcITvd4l{KEG|c3H5 NX\VXpRYOTByzszN NEPRPWUycA>? MnfubY5pcWKrdIOgd4Vve2m2aYrheIlwdiC2bzDUVmFKVCC3cH;uJG1VTEhiZH;3ck1z\We3bHH0bY9v MXyyN|QxQDR{OR?=
HeLa  MnLqRZBweHSxc3nzJGF{e2G7 NW\tdlA5OTByzszN M1PHdVJp MVTicI9kc3NiSmLTMVE2KEmwZIXj[ZMhSXCxcITveIlkKEOnbHygSIVifGh? NX7lcIYxOjN|NESwOFU>
Ec109 NWLnSZVZSXCxcITvd4l{KEG|c3H5 MoThNVDPxE1? NXrscnFqPmh? NEHUUJJjdG:la4OgZZBweHSxdHnjJINwdWKrbnH0bY9vKG:oIGTheE1UdWGlTkegZY5lKHKjZHnheIlwdg>? Mlu0NlM{Ozh3Nki=
H460  M3TnUmFxd3C2b4Ppd{BCe3OjeR?= MmriNVDPxE1? NUfi[VVyPmh? NYW2R443[myxY3vzJIFxd3C2b4TpZ{Bkd22kaX7heIlwdiCxZjDUZZQuW22jY163JIFv\CC{YXTpZZRqd25? NGXHeG0zOzN|OEW2PC=>
HeLa  NW\FdIxVSXCxcITvd4l{KEG|c3H5 NHnRSpM2OM7:TR?= M2LPVVEvPWh? MVThZpJw\2G2ZYRCpGNpdGGveXTpZU1qdmS3Y3XkJIFxd3C2b4Ppdy=> Mo\2NlM{ODN6MES=
SK-HEP1 NF3TT5ZCeG:ydH;zbZMhSXO|YYm= NWr4NY1pOTByzszN MkfONYg> M324c4lvcGmkaYTzJGNzXDFiYXP0bZZifGWmIHPhd5Bie2VvMzygMVctKC16LDCtPUwh[W6mIIDvcJkpSUSSLYLpZo9{\SlicH;sfY1memG|ZR?= M4HUbFI{OzB{NkWw
QGY7701 NYjVS4tFSXCxcITvd4l{KEG|c3H5 NVjHRpNlOjYQvF2= MXixMlVp M3TuNolvcGmkaYTzJIFk[3WvdXzheIlwdiCxZjDzeYIuTzFicHjhd4UhcW6mdXPl[EBjgSCGT2igL{ByfWW{Y3X0bY4> MlnHNlMzPDByNkG=
HepG2 MYfBdI9xfG:|aYOgRZN{[Xl? M3XGd|Ix|ryP Mm[2N|BucW5? M1[3RolvcGmkaYTzJJRp\SCnbnjhcoNm\CClZXzsJIRm[XSqIHL5JINwdWKrbnXkJJRz\WG2bXXueEBw\iCjcHnn[Y5qdiCjbnSgWHJCUUx? MWKyN|IzPDJ|OR?=
U87  MkX4RZBweHSxc3nzJGF{e2G7 M4\pdFI2|ryP MXKybC=> Ml3D[IVkemWjc3XzJIl{d2yrcYXpdol1cWenbnnuJEhKW0xrLXnu[JVk\WRiYYDvdJRwfGmlIHPlcIwh\GWjdHisJIJ2fCCwb4SgcoVkem:2aXOgZ4VtdCCmZXH0bC=> M{e2clI{OjJ7NkK2
HSC-2 NVLFZm5jSXCxcITvd4l{KEG|c3H5 M3;SclI2NzVyzszN NUDrWppVOWh? MXHpcohq[mm2czDTUk0{QC2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?= MnntNlMyPTV{NEi=
HSC-4 NHvEUpBCeG:ydH;zbZMhSXO|YYm= MW[yOU82OM7:TR?= NETmTpkycA>? NXrnSHE4cW6qaXLpeJMhW05vM{itbY5lfWOnZDDjfZRwfG:6aXPpeJk> M3fQelI{OTV3MkS4
CL-1 NHv1emNCeG:ydH;zbZMhSXO|YYm= NHzjWoQzOM7:TR?= MV:xbC=> NHu4XopjdG:la4OgU3A1PDliaX7keYNm\CClZXzsJIRm[XSq M1i4VlI{OTNzN{iy
MEL MnX5RZBweHSxc3nzJGF{e2G7 Mkj4NlDPxE1? MYCyOIg> M4PlfGROW09? MWrpcZBicXKnczDQNng4NWmwZIXj[YQhVUWOIHPlcIwh[XCxcITvd4l{ NHHjW5UzOzBzNEi4Oy=>
Bel-7402  NF7kbXBE[XOyYYPlJGFkfGm4YYTpc44hSXO|YYm= MlP4OVDPxE1? MVWybC=> MX\pcohq[mm2czDQR2UucW6mdXPl[EBidm:ra3nz MXiyN|AxQDd2Mh?=
Eca-109 MXXBdI9xfG:|aYOgRZN{[Xl? NWLnNXBJOjYQvF2= NWrHbYYyOzCvaX6= NHfCdGtqdmirYnn0d{BDUi2EMUGtbY5lfWOnZDDj[YxtKGSnYYTo M4TFXFI{ODd4OU[3
MEL M4nObWFxd3C2b4Ppd{BCe3OjeR?= MkXVNlDPxE1? NYmxSFZkOWh? MYXEUXNQ NFPJPGpqdXCjaYLld{BROlh5LXnu[JVk\WRiTVXMJINmdGxiYYDvdJRwe2m| MUeyN|AyPDh6Nx?=
Bel-7402  NVXmVHZtSXCxcITvd4l{KEG|c3H5 MVe1NO69VQ>? MUGybC=> MkK2bY5pcWKrdIOgVGNGNWmwZIXj[YQh[W6xaXvpdy=> MnTZNlMxODh5NEK=
L929 MoXPSpVv[3Srb36gRZN{[Xl? MoXNNk42|ryP MVuxbC=> M2Phcolv[3KnYYPld{BTUVBzIHX4dJJme3Orb36gZY5lKGW6YXPldoJifGWmIGTOSu6yNWmwZIXj[YQhdWm2b3Poc45lemmjbDDkfZNnfW6ldHnvckBidmRiUl;TJJBzd2S3Y4Tpc44> MnzMNlMxODB3MUi=
RCC  M3;iZ2NmdGxiVnnhZoltcXS7IFHzd4F6 NUe5c5dEOTByzszN NXTteWtVOjSq MmLBdoVkd3[ncnXzJJRp\SC4aXHibYxqfHlib3[gZ4VtdHNiZYjwc5Nm\CC2bzCxOYQuWEeMMh?= M{\pZ|IzQTlzNEm0
NB2a/d1 NX7HeZlvSXCxcITvd4l{KEG|c3H5 NGL6WXoyODEQvF2= M{nwc|czcA>? NG\YRVZifHSnboXheIV{KHO2YYXyc5Nxd3KrbnWtbY5lfWOnZDDjZZNx[XOnIHHjeIl3cXS7LDDQRXJRNCCjbnSgeIF2KGOuZXH2ZYdm NW\3blg3OjJ7OEi1OFE>
T cell MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWn0WnJlOjVvMUCw{txO M1T3T|I1cA>? M1[zbIRwe2VvZHXw[Y5l\W62bImgbY5pcWKrdHXkJHQh[2WubDDwdo9tcW[ncnH0bY9vKG2nZHnheIVlKHSqcn;1[4ghfGinIHPvMZN1cW23bHH0bY9vKHerdHigZY51cS2FREOgZY5lKGGwdHmtR2QzQA>? Ml3qNlI6QDJ3M{i=
K562 NWXreXc1SXCxcITvd4l{KEG|c3H5 NGe3XG0yODEQvF2= NYm5fmNVOWh? M2DheoJtd2OtczDBZo5w[mG4aYPjeY3DqEZvaX7keYNm\CCjcH;weI9{cXN? NU\RTmx7OjJ7N{KzO|I>
Jurkat  NUi3[YFGSXCxcITvd4l{KEG|c3H5 NH;UV|g1OM7:TR?= MlGzNYg> NHPBNYNi[m:uaYPo[ZMhTmG|TD3pcoR2[2WmIHPhd5Bie2ViYXP0bZZifGmxbjDhcoQh[2WubDDk[YF1cA>? NYXPNFJ{OjJ7NEK3N|g>
BGC-823 MmfZRZBweHSxc3nzJGF{e2G7 MWmxNFDPxE1? MljXNYg> NVLrbYU5eGG{dHnhcIx6KHKnc3P1[ZMh[2WubIOgZYdicW6|dDDkZY1i\2Vib3[g[IFq\HqnaX6= NXHmSoV7OjJ7Mk[1OFU>
Hep3B NIfKO5lCeG:ydH;zbZMhSXO|YYm= NFvvUpU2OM7:TR?= MV[xbC=> NIHiW5JjdG:la4OgZZBweHSxc3nzJIlv\HWlZXSgZpkhUEWJQ4O= NGi2N5QzOjl{M{G1OC=>
LLC-PK1 MnLXRZBweHSxc3nzJGF{e2G7 MVKyNO69VQ>? MUmxbC=> NYjrT3ZneHKndnXueJMh[2m|cHzheIlvNWmwZIXj[YQh\GWpcnHkZZRqd25ib3[gRZRoPSxiYnXjcIlvNTFuIHHu[EBCfGdzMjDwdo91\Wmwcx?= MVqyNlg6PjB|Nx?=
A549 NIPaRVNCeG:ydH;zbZMhSXO|YYm= NHPtUFI2OM7:TR?= MofrNYg> MnTuZoxw[2u|IITo[UBDSUlvaX7keYNm\CCjcH;weI9{cXQEoB?= MXOyNlg5PzJzNR?=
SGC-7901  Mn\JRZBweHSxc3nzJGF{e2G7 MmTiNVDPxE1? M3niUlI1cA>? M1vDWolvcGmkaYTzJO6zNM7{LXTpcYV1cHmuYXPyfYx{cGmtb37pck1qdmS3Y3XkJIFxd3C2b4Ppd:Kh M2PtN|IzQDR6NUm3
DM6 MXvBdI9xfG:|aYOgRZN{[Xl? MXuxNFDPxE1? M4iySlczcA>? MXzicI9kc3NiYn;0bEBGOkZvMTDhcoQhTTKIdIKtcYVlcWG2ZXSgZ5l1d3SxeHnjbZR6 NX\SS3B[OjJ6MkWzNlg>
MCF-7, MDA-MB-468, Caco-2 Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\MOoZ2PTEQvF2= M2DaflQ5cA>? MlPubY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnubIljcXSrb36gbY5lfWOnZDDifUB{[XCxbnnu M1r0NVIzQDByOU[4
A2750  NVfv[3JvSXCxcITvd4l{KEG|c3H5 NYTUZWJ6OjEQvF2= NHrHXmIzcA>? MkLaSG1UVw>? NXSxZYh6[myxY3vzJINie3Cjc3WgZ4xm[X[jZ3Wg[JVzcW6pIHjlcIVv[WyrbjD0doVifG2nboSgZY5lKHKnZIXj[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq MnTjNlI4QDR|NkO=
U87  NW\PdZNHSXCxcITvd4l{KEG|c3H5 Mof4NlDPxE1? NGXqfFYzPGh? NVzrT5BCemWmdXPld{B1cGViYYDvdJRwe2m|IILheIUhcW6mdXPl[EBjgSCSTFHC Mo\hNlI4Pzh5OEC=
HT1080 MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrOXYoxPTEQvF2= NFnJTIE4\A>? NEHiWVVqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY5pcWKrdHnvckBk[XW|ZXSgZpkh[2:vYnnu[YQhfHKnYYTt[Y51KG:oIFTDRUBidmRiT13Q MVeyNlc1ODl6NB?=
A549  MXTBdI9xfG:|aYOgRZN{[Xl? MYO1NO69VQ>? NF24OoYzcA>? MkjUdIFzfGmjbHz5JIRm[3KnYYPld{B{d2SrdX2gd4Vt\W6rdHWtbY5lfWOnZDDhdI9xfG:|aYO= M4n3S|IzPzJzOEC0
Primary OPC M{DvbGFxd3C2b4Ppd{BCe3OjeR?= NIrENZcy|ryP NF;QepQ3cC9{NHi= Mne4doVlfWOnczD0bIUheGW{Y3XueIFo\SCxZjDj[YxteyCrbjDlZZJtgS1iYX7kJIxifGVvYYDvdJRwe2m|L37lZ5Jwe2m| NUPHVHpZOjJ5MEezPFU>
PMNs NFX1dmxCeG:ydH;zbZMhSXO|YYm= M3qwR|Qx|ryP NXvMOHZbPmh? Mn7pSG1UVw>? M3\wNZJmfmW{c3XkJJRp\SCjbX;1cpQhd2ZiY3zlZZZm\CClYYPwZZNmNTNidH:gcoVieiC4ZXjpZ4xmKGyndnXsdy=> MkjLNlI3QTJ3N{e=
A549  NVL3eW84SXCxcITvd4l{KEG|c3H5 Mmq1OVDPxE1? NEjKbIgycA>? NVH2bY44eHKndnXueJMh[XCxcITvd4l{KGmwZIXj[YQh[nliQnHvbJVwe2mmZTDJ NH3BOI4zOjZ6N{[zOS=>
AGS NEfUbHhCeG:ydH;zbZMhSXO|YYm= M4nlT|Ix|ryP NVWzcYVGOTKq MniybY5pcWKrdIOgeIhmKGGldHn2ZZRqd25ib3[gdJJwNWOjc4Dhd4UuOyCrbjDy[ZNxd26|ZTD0c{B1cGViRYTPRYMh\nKjY4Tpc44> NInJeowzOjZ6N{O5PC=>
shC9  MXjBdI9xfG:|aYOgRZN{[Xl? MorTNVDPxE1? MWWxOog> M3ziXYJtfW62czDTTGgh\XiycnXzd4lwdiCrbjDzbGM6KGOnbHzzJIV5eG:|ZXSgeI8h\Wm2aHXyJHBCKG:{IFzQRy=> MYqyNlY1OTB7NB?=
primary MEFs NGWycHZHfW6ldHnvckBCe3OjeR?= NHLpUWIyOmh? NH:zbVTDqGmwY4LlZZNmeyCndH;wc5Nq\GVvaX7keYNm\CCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJIRmeG:uYYLpfoF1cW:w NUHo[5V7OjJ4MUO3Olc>
3T9 MEFs MmLlSpVv[3Srb36gRZN{[Xl? NFzHcHkyPmh? MoDkbY5kemWjc3XzJIN6fG:laILvcYUh[yC{ZXzlZZNmKGGodHXyJIV1d3Cxc3nk[U11emWjdH3lcpQ> NVzIUWE3OjJ4MUO3Olc>
3T9 MEFs NFfm[2VHfW6ldHnvckBCe3OjeR?= MYqxPIg> MUP1dJJm\3WuYYTld{Bqdmm2aXH0c5Ih[2G|cHHz[U06KGK3dDDkc5dvemWpdXzheIV{KGWoZnXjeI9zKGOjc4Dhd4V{KGGodHXyJIV1d3Cxc3nk[UB1emWjdH3lcpQ> M2HoR|IzPjF|N{[3
MDA-MB-231  MWnBdI9xfG:|aYOgRZN{[Xl? M{DH[|Ix|ryP M4jYUVRl NH3nbVRz\WS3Y3XzJJRp\SClZXzsJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KG2ndH\vdo1qdiC2cnXheI1mdnRid3HzJJNq\26rZnnjZY51dHl? NEW4O|MzOjV7M{S0NS=>
C6  MkPaRZBweHSxc3nzJGF{e2G7 MnvZNVDPxE1? M2D6OVI1cA>? MYjicI9kc3NidHjlJJN2eHC{ZYPzbZZmKGWoZnXjeEBw\iC2aHWgdIVxfGmmZTDvckB3cWGkaXzpeJk> NWK5bIxVOjJ3OEi5PFA>
HL-60  NH\JfohCeG:ydH;zbZMhSXO|YYm= MlLlNVAx|ryP MYmyOIg> MlnBbY5pcWKrdIOgeIhmKGOnbHygZZBweHSxc3nzJJNmdGWldHXkJEgsMS2vZX70bJltKM7{LTix5qaTPilvZHnncJVkd3C7cnHuc5Nq\GYEoEW= NELIc44zOjV2Nk[2PS=>
HL-60 NEfocmFCeG:ydH;zbZMhSXO|YYm= NXflUHJWOTBvOEFOwG0> M3fsOFRp M3LoVYlvcGmkaYTzJHRIUFFvaX7keYNm\CClZXzsJIFxd3C2b4Ppd:Kh NUm4ZmdsOjJ3MkOyNlk>
BCC MV7BdI9xfG:|aYOgRZN{[Xl? NFX2dnA2OM7:TR?= M{O1dVFp M3i1UIlvcGmkaYTzJGRCXFNvbXXkbYF1\WRiZ4Lve5RpKGmwaHnibZRqd25? M1;zOVIzPTF7NEO2
RAW 264.7 M4f1UWFxd3C2b4Ppd{BCe3OjeR?= NXj3cFh4PTBxMUCw{txO MVWxbC=> NIPN[YVkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcohq[mm2czDEU24ucW6mdXPl[EBzWk6DIHPs[YF3[Wen MkTINlI1QTF2Mk[=
K562 MnSyRZBweHSxc3nzJGF{e2G7 MYqyOe69VQ>? NV\OSIQxOmh? M3vNdJBz\X[nboTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGOxLYTy[YF1dWWwdDD3bZRpKGGvdYLlcpNqdiCJIHHu[EBVWkGLTB?= MmTQNlI1QDN5N{e=
SGC-7901 MVzBdI9xfG:|aYOgRZN{[Xl? M1vrflIxKM7:TdMg MXOybC=> NIHlSYxifHSnboXheIV{KEh{T{NCpI9zKFSQRjFOtU1qdmS3Y3XkJINmdGxiYYDvdJRwe2m|IHHzJJdmdGxiYYOgZ4F{eGG|ZT2zJIFkfGm4aYT5xsA> M4fVdFIzPDdzNUi5
PC3 M{XxRWFxd3C2b4Ppd{BCe3OjeR?= MX2xNO69VQ>? M2XaRlRp NIHYT5Bkd3WwdHXyd{BndGG4b3PvfIllNWmwZIXj[YQh[2G|cHHz[U1z\WyjdHXkJIFxd3C2b4Ppdy=> NXnPS2VmOjJ2N{G5O|Q>
SMMC-7721 NUTIfpUxSXCxcITvd4l{KEG|c3H5 NIfyWlA2OM7:TR?= NI\2XIw1QGh? M{\Ub4F1fGWwdXH0[ZMhd1SULXnu[JVk\WRiYYDvdJRwe2m| NHOw[G8zOjR4NUizNy=>
HeLa  M13JUGFxd3C2b4Ppd{BCe3OjeR?= M4L2[lUxyqEQvF2= M3vRcFQwQGh? NELNZndqdmirYnn0d{BUXFNvaX7keYNm\CCuYYTlMZBp[XOnIHHwc5B1d3SrYzDleoVvfHN? M4i0[FIzPDZyNUC0
HeLa  NIfCVZVCeG:ydH;zbZMhSXO|YYm= NUfZdWtHPTEEoN88US=> NGeyb5QycA>? NIrhN3F{fXCycnXzd4V{KHSqZTDGVmFRNWmwZIXj[YQh[WOldX31cIF1cW:wIH;mJIFvdmW6aX6gWkBxd3OrdHn2[UBk\Wyucx?= NVXFS406OjJ2NEm0OFA>
T47D  M1fFSWFxd3C2b4Ppd{BCe3OjeR?= M{[xSVExOM7:TR?= MoLLNYg> NHrmdG5jdG:la4OgeIhmKGenbnXyZZRqd25ib3[gSU1k[WRxQ2TGNkBjgSCVVGO= NXK2UXRlOjJ2MEGxOlg>
HeLa  MmrPRZBweHSxc3nzJGF{e2G7 NEfPS5Q{OM7:TR?= M3HjUlRp MnntxsBqdmO{ZXHz[ZMhfGinIHflcoVz[WxiY3XscEB3cWGkaXzpeJkhPDhiaDDh[pRmeiCyaH;0c4R6dmGvaXOgeJJm[XSvZX70xsA> NF:2coMzOjN7NEK0PC=>
HCC MUHBdI9xfG:|aYOgRZN{[Xl? M4rZdVIxKM7:TdMg MlrlNog> NIW2OHRifHSnboXheIV{KHSqZTDETGEhcW6mdXPl[EBi[3SrdnH0bY9vKG:oIGDBVnA> M1GxSVIzOzR{N{Oy
mESCs NHS5OWJCeG:ydH;zbZMhSXO|YYm= M1;XSFIvPc7:TR?= NGnTT4ozcA>? MWfpcohq[mm2czD0bIUhVmGILX3l[IlifGWmIHPhd5Bie2ViYXP0bZZifGmxbh?= MkTZNlIzQDV{N{S=
EMT-6  MnzZR5l1d3SxeHnjbZR6KEG|c3H5 NVfRWms4OTByzszN NUCweJpTOWh? MYPwZZJ1cWGubImgZoxw[2unZDDj[YxtKGSnYYToJIlv\HWlZXSgZpkhe2m{YX3ld4lv\Q>? M2P4WlIzOjVzOUKx
MCF7 MV;BdI9xfG:|aYOgRZN{[Xl? NVXpXpB3PTEEoN88US=> NVTV[ldNOWh? MlXhbY5pcWKrdIOgVGEh[WO2aY\heIVlKGOjc4Dhd4UuOyxiLUmsJIFv\CCyb3z5LGFFWC2{aXLvd4UqKHCxbInt[ZJie2V? NWXPWJRbOjJ{MkOzOFU>
K562 NELafW1CeG:ydH;zbZMhSXO|YYm= M1L2OVIxKM7:TdMg NFzLc5I1QGh? M2G5RmROW09? M175eIJtd2OtczDsZZBifGmwaXKtbY5lfWOnZDDpcohq[mm2aX;uJI9nKH[rYXLpcIl1gSCjbnSgZZBweHSxc3nzJIlv\HWldHnvci=> M1\kT|IzOjF4MUW4
Molt4-hyg MlX2RZBweHSxc3nzJGF{e2G7 MnLPNVDPxE1? NEm0T4sxNjWq NFfXOFFjdG:la4Og[oFzdmW|b3ytbY5lfWOnZDDjZZNx[XOnLUOtcIls\SCjY4Tpeol1gQ>? NUPhNmRTOjZ{N{W4NVE>
HeLa MXPBdI9xfG:|aYOgRZN{[Xl? MVuxNO69VQ>? MoDUNE42cA>? NYfUSFcxcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nlidHjlJINwdWKrbnXkJJRz\WG2bXXueEB4cXSqIHfvcYl{cW5iTjDhcoQhXFKDSVy= MXqyNlE4QTZ4MR?=
Jurkat T NX25TmU4SXCxcITvd4l{KEG|c3H5 NX7MfIYzOzEQvF2= NH\1Zm4xNjWq NXHVSmp2TE2VTx?= MV\icI9kc3NidHjlJJpqemGvLXnu[JVk\WRiYYDvdJRwe2m| NFu0U3IzOjF3OUi5PC=>
Neutrophil MmLaRZBweHSxc3nzJGF{e2G7 M1;MVFIx|ryP M3PCOFAvPWh? MVXheJRmdnWjdHXzJJRp\SCycn:tZZBweHSxdHnjJIVn\mWldDDv[kBO[VJz NUjrdJhlOjZzOU[4OFQ>
HCT116 M1XsfGFxd3C2b4Ppd{BCe3OjeR?= NFzYdoI2OMLizszN NFnaRYczcA>? NFzpdolz\X[ncoPld{B{gW6ncnfpd5Rq[yCjcH;weI9{cXNiZX\m[YN1eyCxZjDj[Yxm[2:6aXKgZY5lKE6SQz2xOuKh MViyNlE2QTd3Mh?=
MDA-MB-231  M4i5RmFxd3C2b4Ppd{BCe3OjeR?= NH\WbGkzNjVvNz61{txO NHTY[mMzcA>? NYnFOHV3cW6qaXLpeJMhfGinIHPlcIwh\GWjdHigc4YhVUSDLV3CMVI{OSClZXzsd{BqdmS3Y3XkJIJ6KFOGVDDpckBiKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70JI1idm6nch?= M2S5W|IzOTF3NUK2
LNCaP NVPyTWpmSXCxcITvd4l{KEG|c3H5 MXW0NO69VQ>? MVuybC=> M{\STolvcGmkaYTzJIJ2fGWrbjDpcoR2[2WmIHPlcIwh[XCxcITvd4l{ NFTlTVAzOjFzNEe2OC=>
MB231 NHvDeZdCeG:ydH;zbZMhSXO|YYm= MlXUNVAx|ryP MVWxbC=> M{nqdmROW09? Mm[3ZYJzd2ejdHXzJJRp\SCrbnT1Z5Rqd25ib3[gZ4VtdCCmZXH0bEBjgSCZRVWxJIlvcGmkaYTpc44tKFSUQVnMJJRz\WG2bXXueEwh[W6mIITo[UBkd22kaX7heIlwdg>? M{\2R|IzOTF{OUSw
HCC38  M2Xx[GFxd3C2b4Ppd{BCe3OjeR?= MoDaNVAx|ryP M2nyO|Fp MkLvSG1UVw>? NF\FfINi[nKxZ3H0[ZMhfGinIHnu[JVkfGmxbjDv[kBk\WyuIHTlZZRpKGK7IGfFSVEhcW6qaXLpeIlwdixiVGLBTWwhfHKnYYTt[Y51NCCjbnSgeIhmKGOxbXLpcoF1cW:w NGrXXnYzOjFzMkm0NC=>
MDA-MB231 NVjUOo9VSXCxcITvd4l{KEG|c3H5 NE[w[Gk2OMLizszN MmPlNlRp MnvPSG1UVw>? NHfieJZi[nKxZ3H0[ZMh[3W{Y4XtbY4ucW6mdXPl[EBk\WyuIHTlZZRp M{TVUVIzOTBzM{O1
LNCaP NYrUWndGSXCxcITvd4l{KEG|c3H5 Mn;HOVDDqM7:TR?= MVOyOIg> MWnEUXNQ M3qxSIFjem:pYYTld{BkfXKldX3pck1qdmS3Y3XkJINmdGxiZHXheIg> M4\vUFIzOTBzM{O1
HCT116 MYTBdI9xfG:|aYOgRZN{[Xl? NGn6bno2OMLizszN MlvhNlRp M{XaemROW09? MlnQZYJzd2ejdHXzJIN2emO3bXnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> M4iyN|IzOTBzM{O1
Ishikawa  MkjlRZBweHSxc3nzJGF{e2G7 MUCyOe69VQ>? MlrCNlRp MoXpdoVlfWOnczDj[YxtKGSnYYToJIFv\CCjcH;weI9{cXNiaX7keYNm\CCkeTDCZYYhSTF? MVOyNlA5QDlzOB?=
 YD-8  NE\xXVdCeG:ydH;zbZMhSXO|YYm= NV\MZW9mOTByzszN NXT6SoZIOWh? MljxbY5pcWKrdIOgVGxGVy2rbnT1Z4VlKGGyb4D0c5Nqew>? MnLnNlIxQDZzOEO=
eosinophil  NHexbolCeG:ydH;zbZMhSXO|YYm= NX;RXFJMQTEQvF2= NHfzcWozPGh? Mnm0bY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhTmG|IHHueIljd2S7wrC= MmSyNlIxPzl|M{S=
L929 MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLyT2ZIOi53zszN M{j2UVI1cA>? NWTSbFhkcW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YheC2yM{igZY5lKE6ILd86RkB1dyCjdXft[Y51KFSQRt8xMYlv\HWlZXSgcoVkem:ydH;zbZMh[W6mIHH1eI9xcGGpeR?= NWHZXZN6OjJyMkewPVc>
YD-8  M1HDfGFxd3C2b4Ppd{BCe3OjeR?= NH:0TmcyODEQvF2= NHnCUpoycA>? NWDtO4xT[myxY3vzJJRp\SCJUz3IR4wucW6mdXPl[EBieG:ydH;zbZM> MYWyNlAzODB5OB?=
HBx M2\NfGFxd3C2b4Ppd{BCe3OjeR?= NHLhd4kzPc7:TR?= MnHJOFhp NUD1TJJFTE2VTx?= NEnTOY9z\WS3Y3XkJINmdGxiZHXheIghcW6mdXPl[EBjgSB|LV3B M1X6UFIzODJyMEe4
U937  M2PFcGFxd3C2b4Ppd{BCe3OjeR?= MnnFOVDDqM7:TR?= Mk[3NYg> MWjpcohq[mm2czDISk1qdmS3Y3XkJIFxd3C2b4Ppd:Kh M3ztb|IyQTl6N{Ox
HL60 M3S4O2Fxd3C2b4Ppd{BCe3OjeR?= Ml;TOFDPxE1? MXS0NI1qdg>? MliwSG1UVw>? MYLicI9kc3NiQl7ER{Bkd22yb4Xu[JMhcW6mdXPlJIV5eG:|dYLlJI9nKHCqb4PwbIF1cWS7bIPldolv\SCjbnSgSG5CKG[{YXft[Y51[XSrb36= NXLNbmhqOjF7OEOyPVY>
M-14 MnzERZBweHSxc3nzJGF{e2G7 MlPtNlXPxE1? M4iy[FAvPWh? NETPXHrDqGmwaHnibZR{KGKxdHigeIhmKGO{dXTlJIV5fHKjY4StJIFv\CClb33wc5Vv\C2rbnT1Z4VlKGGyb4D0c5Nqew>? MUeyNVk2PDl3OR?=
SK-BR-3 MWXBdI9xfG:|aYOgRZN{[Xl? MUS1NOKh|ryP MVmybC=> M{mwO4Jtd2OtczDhdI9xfG:2aXOgSG5CKG[{YXft[Y51[XSrb36gbY5lfWOnZDDifUBkd22kaX7heIlwdiCxZjDTUU0yPjRiYX7kJJJi\GmjdHnvci=> NHfWVnozOTlyMUO4Oi=>
MDA-MB-468 NWCycItOSXCxcITvd4l{KEG|c3H5 NH;keZE2OMLizszN NFnMfmszcA>? NGDKZ5RjdG:la4OgZZBweHSxdHnjJGRPSSCocnHncYVvfGG2aX;uJIlv\HWlZXSgZpkh[2:vYnnuZZRqd25ib3[gV20uOTZ2IHHu[EBz[WSrYYTpc44> M{\adFIyQTBzM{i2

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
IRF-1 / p-STAT1 / cleaved PARP1 / cleaved-caspase3; 

PubMed: 27191889     


With the addition of Z-VAD-FMK, levels of cleaved Caspase-3 and PARP1 were decreased.

Beclin1 / Atg5 / Atg7 / LC-3I / LC-3II; 

PubMed: 27191889     


Levels of Beclin1, Atg5, Atg7 and LC3-II were decreased after IFN-γ stimulation. However, when IFN-γ was combined with the caspase inhibitor, levels of Beclin1, Atg5, Atg7 and LC3-II were not decreased as determined by the Western Blot test. 

p23 / Hsp90 / hTRET / MMP2; 

PubMed: 19740745     


Expression of Hsp90 client proteins during cell death. HeLa cells were preincubated with z-VAD-fmk (100 μM) for 1 h and exposed to various concentrations of tunicamycin (Tu, in μM) for 24 h. Cell extracts were prepared and analyzed by Western blotting. β-Actin was used as the loading control.

cyto C; 

PubMed: 17301139     


z-VAD-fmk did not inhibit cytochrome c release in RRV-infected MA104 cells (RRV: rhesus rotavirus). Mock- and RRV-infected MA104 cells either were not pretreated or were pretreated with 100 μM z-VAD-fmk for 2 h before RRV infection, and treatment was continued during infection. Fourteen hours after RRV infection, the cytosolic and heavy-membrane fractions were assayed for cytochrome c by Western blotting. Mock-infected MA104 cells were used as negative controls. Cox IV and tubulin were used as protein loading controls for the heavy-membrane and cytosolic fractions, respectively. Positions of molecular weight markers are indicated on the left.

27191889 19740745 17301139
Growth inhibition assay
Cell viability; 

PubMed: 12522090     


Inhibition of magnolol-induced apoptotic cell death by z-VAD-fmk. CH27 cells were treated with cell permeable broad-spectrum caspase inhibitor (z-VAD-fmk) 2 h prior to 80 μm magnolol treatment. Cell viability was estimated. ***P<0.001, compared with the 80 μM magnolol-treated group. 

12522090
Immunofluorescence
cytochrome c ; 

PubMed: 11726499     


Immunolocalization of Smac/DIABLO and cytochrome c in HeLa cells. (A-C) Viable (non-apoptotic) HeLa cells were stained with antibodies to cytochrome c (green) and Smac/DIABLO (red) as indicated. Note that both proteins clearly co-localize within punctate, mitochondrial structures. (D–F) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were UV-irradiated followed by further incubation for 8 h. Note the cells where cytochrome c has exited mitochondria and can be seen in a diffuse pattern throughout the cell, including the nucleus (white arrows). In the latter case, note the retention of Smac/DIABLO in punctate mitochondrial structures within the cytoplasm. (G-I) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were then treated with 10 µM actinomycin D for 8 h. Once again note the retention of Smac/DIABLO in mitochondrial structures. (J-L) HeLa cells were treated as described in (G-I). A close-up of a single cell that has undergone mitochondrial cytochrome c release, but where Smac/DIABLO is retained within mitochondria, is shown.

Smac/DIABLO; 

PubMed: 11726499     


Immunolocalization of Smac/DIABLO and cytochrome c in HeLa cells. (A-C) Viable (non-apoptotic) HeLa cells were stained with antibodies to cytochrome c (green) and Smac/DIABLO (red) as indicated. Note that both proteins clearly co-localize within punctate, mitochondrial structures. (D–F) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were UV-irradiated followed by further incubation for 8 h. Note the cells where cytochrome c has exited mitochondria and can be seen in a diffuse pattern throughout the cell, including the nucleus (white arrows). In the latter case, note the retention of Smac/DIABLO in punctate mitochondrial structures within the cytoplasm. (G-I) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were then treated with 10 µM actinomycin D for 8 h. Once again note the retention of Smac/DIABLO in mitochondrial structures. (J-L) HeLa cells were treated as described in (G-I). A close-up of a single cell that has undergone mitochondrial cytochrome c release, but where Smac/DIABLO is retained within mitochondria, is shown.

Endo G; 

PubMed: 12941691     


GFP-Bax expression and immunostaining of EndoG together with nuclear Hoechst staining in HeLa cells 18 h after transient transfection with a vector encoding GFP-Bax in the absence or in the presence of the caspase inhibitor z-VAD-fmk (100 μM). 

AIF; 

PubMed: 12941691     


GFP-Bax expression and immunostaining of AIF together with nuclear Hoechst staining in HeLa cells 18 h after transient transfection with a vector encoding GFP-Bax in the absence or in the presence of the caspase inhibitor z-VAD-fmk (100 μM). 

11726499 12941691
ELISA
IL-1β; 

PubMed: 26254306     


Cell-free medium supernatants were harvested at 5 h. IL-1β levels were measured by ELISA. Z-VAD-FMK was used as a positive control. Bars represent means ± sem of pooled results from 3 experiments performed in triplicate at different times.

26254306
In vivo In vivo Z-VAD-FMK administration has been shown previously to be nontoxic and to prevent apoptosis in animal models. Intraperitoneal HK-GBS injection leads to preterm delivery, and pretreatment with Z-VAD-FMK delays preterm delivery in mice. In OVA-sensitized mice,treatment of z-VAD-fmk inhibits allergen-induced leukocyte infiltration. Systemic injection of the pan-caspase inhibitor z-VAD-fmk immediately before OVA challenge reduced inflammatory cell accumulation, mucus hypersecretion, and Th2 cytokine release in OVA-sensitized/challenged mice. Treatment with z-VAD-fmk blocked terminal differentiation of lens epithelial cells and keratinocytes, the differentiation of monocytes into macrophages, and the differentiation of erythroid progenitors. z-VAD-fmk attenuated allergen-induced airway inflammation and hyperreactivity. Treatment with z-VAD-fmk in vivo also prevented subsequent T cell activation ex vivo[7].

Protocol

Cell Research:

[6]

- Collapse
  • Cell lines: human granulosa cell lines (GC1a, HGL5, COV434)
  • Concentrations: 50 μM
  • Incubation Time: 48 h
  • Method:

    To validate the efficacy of Z-VAD-FMK, three human granulosa cell lines (GC1a, HGL5, COV434) were treated for 48 h with etoposide (50 μg/ml) and/or Z-VAD-FMK (50 μM) under normoxic conditions. To mimic the ischemic phase that occurs after ovarian fragment transplantation, cells were cultured without serum under hypoxia (1 % O2) and treated with Z-VAD-FMK. The metabolic activity of the cells was evaluated by WST-1 assay. Cell viability was determined by FACS analyses. The expression of apoptosis-related molecules was assessed by RT-qPCR and Western blot analyses.


    (Only for Reference)
Animal Research:

[7]

- Collapse
  • Animal Models: CD1 mice
  • Formulation: dissolved in DMSO, diluted in PBS (final concentration of DMSO < 1%)
  • Dosages: 10 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 93 mg/mL (198.93 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+35 %PEG 300+2%Tween 80+ddH2O
For best results, use promptly after mixing.
6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 467.49
Formula

C22H30FN3O7

CAS No. 187389-52-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you suggest an in vivo formulation of S7023 for animal studies?

  • Answer:

    For in vivo study of S7023, The IP formulation is 2% DMSO+35 % PEG 300+2% Tween 80+ddH2O up to 6 mg/ml. The gavage formula is 1%CMC-Na up to 30 mg/ml (suspensions).

  • Question 2:

    What is difference between S7023 & S8102?

  • Answer:

    Unlike S7023, S8102 does not require pretreatment with esterase for in vitro studies. This information was cited from the article: https://www.ncbi.nlm.nih.gov/pubmed/16973565.

Caspase Signaling Pathway Map

Related Caspase Products

Tags: buy Z-VAD-FMK | Z-VAD-FMK supplier | purchase Z-VAD-FMK | Z-VAD-FMK cost | Z-VAD-FMK manufacturer | order Z-VAD-FMK | Z-VAD-FMK distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID